VBI Vaccines (VBIV) Set to Announce Quarterly Earnings on Friday

VBI Vaccines (NASDAQ:VBIV) will be releasing its earnings data on Friday, April 5th.

VBI Vaccines Trading Down 11.2 %

Shares of VBIV stock traded down $0.08 on Thursday, reaching $0.67. The company’s stock had a trading volume of 1,864,107 shares, compared to its average volume of 248,069. The stock’s fifty day simple moving average is $0.62 and its 200-day simple moving average is $0.62. VBI Vaccines has a 1 year low of $0.45 and a 1 year high of $5.82. The company has a market capitalization of $15.83 million, a price-to-earnings ratio of -0.06 and a beta of 1.93.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of VBI Vaccines in a research note on Tuesday. They set a “sell” rating for the company.

Institutional Trading of VBI Vaccines

Large investors have recently made changes to their positions in the stock. Engineers Gate Manager LP purchased a new stake in VBI Vaccines in the first quarter worth about $26,000. Point72 Hong Kong Ltd purchased a new stake in shares of VBI Vaccines during the second quarter valued at about $29,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of VBI Vaccines during the second quarter valued at about $131,000. BNP Paribas Arbitrage SA lifted its position in shares of VBI Vaccines by 208.7% during the second quarter. BNP Paribas Arbitrage SA now owns 47,668 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 32,227 shares during the last quarter. Finally, Centiva Capital LP purchased a new stake in shares of VBI Vaccines during the second quarter valued at about $45,000. 12.26% of the stock is owned by hedge funds and other institutional investors.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.